Abcam, ab280573, Anti-IL-6R antibody [EPR24322-143] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal IL-6R antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24322-143,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IP, IHC-P, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab280573 is the carrier-free version of
ab271042
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IL-6R also known as the IL-6 receptor or IL-6R protein is a transmembrane protein with an approximate mass of 80-90 kDa. This receptor is found on the surface of various cells including hepatocytes leukocytes and immune cells like T-cells and macrophages. IL-6R binds to interleukin-6 (IL-6) a cytokine and plays an important role in immune response regulation. The receptor exists in both membrane-bound and soluble forms each contributing to diverse signaling events.
Biological function summary
IL-6 receptor function involves mediating the effects of IL-6 through its interaction with glycoprotein 130 (gp130) forming a signaling complex. This complex initiates intracellular pathways that lead to gene expression changes necessary for immune responses inflammation and hematopoiesis. When IL-6 binds IL-6R the complex formation with gp130 triggers downstream signaling that impacts cell growth differentiation and survival.
Pathways
IL-6R is central to the JAK/STAT signaling pathway one of the two main pathways activated by IL-6 signaling. It's also involved in the MAPK cascade contributing to cellular responses such as proliferation and differentiation. Through these pathways IL-6R interacts with other proteins like JAK kinases and STAT transcription factors coordinating cellular responses to external signals.
IL-6R is associated with inflammatory diseases such as rheumatoid arthritis and certain cancers. In rheumatoid arthritis overexpression of IL-6R leads to persistent inflammation and joint damage. In cancer IL-6/IL-6R signaling promotes tumorigenesis and cancer cell survival through interactions with proteins like STAT3. Understanding these connections aids in developing therapeutic interventions targeting IL-6R in various pathological conditions.